title: [Is GHB use in Switzerland on the rise?].
authors.affiliation: Forschungsgruppe Substanzstörungen, Psychiatrische Universitätsklinik Zürich. hans-rudolf.pfeifer@puk.zh.ch
authors.forename: H R
authors.initials: HR
authors.lastname: Pfeifer
authors.forename: R
authors.initials: R
authors.lastname: Stohler
mesh_terms: D015107:4-Butyrolactone / Q000008:administration & dosage / Q000494:pharmacology; D000759:Adjuvants, Anesthesia / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000284:Administration, Oral; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D006801:Humans; D013287:Illicit Drugs; D012978:Sodium Oxybate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000506:poisoning / Q000627:therapeutic use; D012997:Solvents / Q000008:administration & dosage; D019966:Substance-Related Disorders; D013557:Switzerland; D013997:Time Factors
chemical_list: D000759:Adjuvants, Anesthesia; D018686:Anesthetics, Intravenous; D013287:Illicit Drugs; D012997:Solvents; D012978:Sodium Oxybate; D015107:4-Butyrolactone
vernacular_title: Zunehmender Konsum von GHB in der Schweiz?